ES2091212T3 - Compuestos de xantina. - Google Patents

Compuestos de xantina.

Info

Publication number
ES2091212T3
ES2091212T3 ES90116791T ES90116791T ES2091212T3 ES 2091212 T3 ES2091212 T3 ES 2091212T3 ES 90116791 T ES90116791 T ES 90116791T ES 90116791 T ES90116791 T ES 90116791T ES 2091212 T3 ES2091212 T3 ES 2091212T3
Authority
ES
Spain
Prior art keywords
chem
compounds
effect
independently represents
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90116791T
Other languages
English (en)
Inventor
Fumio Suzuki
Junichi Shimada
Akio Ishii
Tetsuji Ohno
Akira Karasawa
Kazuhiro Kubo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of ES2091212T3 publication Critical patent/ES2091212T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/20—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

NUEVO COMPUESTO XANTINA REPRESENTADO POR LA SIGUIENTE FORMULA: EN DONDE CADA UNO DE LOS R1, R2 Y R3 REPRESENTAN INDEPENDIENTEMENTE UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO INFERIOR; CADA UNO DE LOS X1 Y X2 REPRESENTAN INDEPENDIENTEMENTE UN ATOMO DE AZUFRE O DE OXIGENO; EN DONDE REPRESENTA UN SIMPLE ENLACE O UN DOBLE ENLACE; Y REPRESENTA UN SIMPLE ENLACE O UN GRUPO ALQUILENO, N REPRESENTA 0 O 1, CADA UNO DE LOS W1 Y W2 REPRESENTAN INDEPENDIENTEMENTE UN ATOMO DE HIDROGENO, UN GRUPO AMINO O ALQUILO INFERIOR, Z REPRESENTA -CH2-, -O-, -SES; ENTONCES R1, R2 Y R3 NO SON SIMULTANEAMENTE METILO. TAMBIEN SE REIVINDICAN SALES DE EL FISIOLOGICAMENTE ACEPTABLES QUE TIENEN EFECTO DIURETICO, UN EFECTO DE PROTECCION RENAL Y/O UN EFECTO BRONCODILATADOR.
ES90116791T 1989-09-01 1990-08-31 Compuestos de xantina. Expired - Lifetime ES2091212T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22664289 1989-09-01

Publications (1)

Publication Number Publication Date
ES2091212T3 true ES2091212T3 (es) 1996-11-01

Family

ID=16848383

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90116791T Expired - Lifetime ES2091212T3 (es) 1989-09-01 1990-08-31 Compuestos de xantina.

Country Status (11)

Country Link
EP (1) EP0415456B1 (es)
JP (1) JPH06102662B2 (es)
AT (1) ATE139778T1 (es)
BR (1) BR1100762A (es)
CA (1) CA2024381C (es)
CY (1) CY2069B1 (es)
DE (1) DE69027562T2 (es)
DK (1) DK0415456T3 (es)
ES (1) ES2091212T3 (es)
GR (1) GR3020715T3 (es)
HK (1) HK1000600A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
EP0541120B1 (en) * 1991-11-08 1999-05-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for the treatment of dementia
US5336769A (en) * 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5342841A (en) * 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
TW252044B (es) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
DE4238367A1 (de) * 1992-11-13 1994-05-19 Boehringer Ingelheim Kg Diuretisches Mittel
WO1994016702A1 (fr) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
WO1995031460A1 (en) * 1994-05-17 1995-11-23 Kyowa Hakko Kogyo Co., Ltd. Process for producing xanthine derivative
EP0799040B1 (en) 1994-12-13 2003-08-20 Euroceltique S.A. Trisubstituted thioxanthines
US6066641A (en) * 1994-12-13 2000-05-23 Euro-Celtique S.A. Aryl thioxanthines
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
US6254889B1 (en) * 1995-07-26 2001-07-03 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
WO1998057644A1 (en) * 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Preventive and remedy for drug-induced nephropathy
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0970696A1 (en) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
CA2333947C (en) * 1998-06-01 2010-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds as adenosine a1 antagonist for male sterility
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
CN100390178C (zh) * 1999-11-12 2008-05-28 拜奥根Idec马萨诸塞公司 作为腺苷受体拮抗剂的多环烷基嘌呤
MXPA02004795A (es) * 1999-11-12 2005-07-01 Biogen Inc Antagonistas del receptor de adenosina y los metodos para producir y utilizar los mismos.
KR20070058022A (ko) 2000-04-26 2007-06-07 에자이 알앤드디 매니지먼트 가부시키가이샤 배변을 촉진하는 의약 조성물
BR0115833A (pt) 2000-12-01 2003-10-28 Biogen Inc Derivados condensados de purina como antagonistas de receptores de adenosina a1
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
EA200500005A1 (ru) * 2002-06-12 2005-06-30 Байоджен Айдек Ма Инк. Способ лечения повреждения, вызванного реперфузией после ишемии, с использованием антагонистов рецептора аденозина
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
DE60322748D1 (de) * 2003-05-06 2008-09-18 Cv Therapeutics Inc Xanthinderivate als a2b-adenosinrezeptorantagonisten
ES2557310T3 (es) * 2003-08-25 2016-01-25 Dogwood Pharmaceuticals, Inc. 8-heteroaril xantinas substituidas
JPWO2007069675A1 (ja) 2005-12-14 2009-05-28 協和発酵キリン株式会社 キサンチン誘導体の易吸収性経口製剤
GB0708258D0 (en) * 2007-04-27 2007-06-06 Katholleke Universiteit Leuven New anti-viral nulceoside analogs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
GB1201997A (en) * 1967-08-04 1970-08-12 Yissum Res Dev Co New substituted purines and purine derivatives
GB8618931D0 (en) * 1986-08-02 1986-09-10 Euro Celtique Sa 6-thioxanthines
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung

Also Published As

Publication number Publication date
GR3020715T3 (en) 1996-11-30
ATE139778T1 (de) 1996-07-15
EP0415456A2 (en) 1991-03-06
DE69027562T2 (de) 1997-02-20
DE69027562D1 (de) 1996-08-01
EP0415456A3 (en) 1991-05-29
CA2024381A1 (en) 1991-03-02
BR1100762A (pt) 2000-03-14
JPH06102662B2 (ja) 1994-12-14
CY2069B1 (en) 1998-09-11
CA2024381C (en) 1997-01-07
JPH03173889A (ja) 1991-07-29
HK1000600A1 (en) 1998-04-09
DK0415456T3 (da) 1996-07-29
EP0415456B1 (en) 1996-06-26

Similar Documents

Publication Publication Date Title
ES2091212T3 (es) Compuestos de xantina.
DK0386675T3 (da) Xanthinderivater
CA2124680A1 (en) Piperazine derivatives as 5-ht1a antagonists
NO302755B1 (no) Morfinan-derivater
EP0031567A3 (en) Tetrapeptidesemicarbazide derivatives and their production and use
FR2593504B1 (fr) Nouveaux derives de dihydrobenzofuranne - et de chromane - carboxamides, leurs procedes de preparation et leur utilisation comme neuroleptiques
DE3864707D1 (de) Benzoxazin-derivate und verfahren zu ihrer herstellung.
ATE71944T1 (de) Thiazolderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
DE3477380D1 (en) Novel benzothiazepine derivatives, processes for preparing the same and pharmaceutical compositions
ES2003086A6 (es) Procedimiento de obtencion de tienoquinolicinsulfonamidas
DE68900990D1 (en) Thioformamid-derivate.
EP0347880A3 (en) Imidazo[2,1-b]benzothiazole compounds and antiulcer compositions containing the same
DK0420224T3 (da) Anthihepatopatisk middel
FI883507A0 (fi) Naftotiazepinderivat och deras framstaellning.
ATE93524T1 (de) Mitomycinanaloge, verfahren zu ihrer herstellung und pharmazeutische zubereitungen.
ATE75468T1 (de) Substituierte 3-aminosydnonimine, verfahren zu ihrer herstellung und ihre verwendung.
AU4370489A (en) The use of oxidized polyamines, especially nn'-bis-(3- propionaldehyde)-1-4-diaminobutane (sperminedialdehyde) as immunosuppressive agents
PH25608A (en) 3-amino-tetrahydro-isoquinoline
MX9701841A (es) Derivados aminoheterociclicos como agentes antitromboticos o anticoagulantes.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 415456

Country of ref document: ES